A 26-year-old woman diagnosed with advanced colorectal cancer says she is now cancer-free after receiving an experimental dual immunotherapy treatment, highlighting new options for younger patients amid rising cancer rates.
Young Patient Beats Advanced Cancer Diagnosis
Mrinali Dhembla, 26, was declared cancer-free in July 2025 after undergoing a new immunotherapy treatment for Stage 3 rectal cancer that had spread to her spine, she said during an interview aired Monday on “Good Morning America.”
Dhembla recalled months of severe back pain and fatigue before doctors identified the illness. She initially struggled to accept the diagnosis because of her age and recent engagement.
“I still remember the doctor telling me that I had cancer, and my first instinct was to say that he was wrong,” Dhembla said. “I said, ‘That’s not possible. I’m just 26 years old.”
Her case reflects a growing concern among health experts as colorectal cancer diagnoses rise among adults under 50. Research cited by the American Cancer Society reports a 2.3% increase in rectal cancer cases and a 1.3% increase in colon cancer cases among people in their 40s since the 1990s
Genetic Condition Leads Doctors to Targeted Therapy
Genetic testing revealed Dhembla had Lynch syndrome, a hereditary condition linked to higher risks of colorectal and other cancers at younger ages. According to the Centers for Disease Control and Prevention, Lynch syndrome affects genes responsible for repairing DNA errors, allowing cancer cells to develop more easily.
Dr. Nicholas Hornstein, an oncologist at Northwell Cancer Institute and one of Dhembla’s physicians, said patients with Lynch syndrome often respond well to immunotherapy.
“Patients who have Lynch syndrome are excellent candidates for immunotherapy,” Hornstein said. “Because they have so many mutations in their cancer cells, it allows their immune system to recognize them.”
Doctors selected Dhembla as one of the first patients to receive a dual immunotherapy treatment approach designed to remove immune system barriers and enable the body to attack tumors directly.
Hornstein said the treatment’s effects can be long-lasting. “Patients who can eradicate their tumors tend to stay gone,” he said.
Treatment Offers Hope as Young Cancer Cases Rise
The dual immunotherapy treatment allowed Dhembla to avoid months of chemotherapy and radiation, typically associated with advanced colorectal cancer treatment. During therapy, she completed three infusions over four months and even ran a 5K race while undergoing treatment.
After treatment concluded, doctors found no evidence of cancer. Since then, Dhembla said she has traveled and resumed planning major life events, including her wedding.
Health experts say her experience underscores the importance of early evaluation of persistent symptoms, especially among younger adults who may not consider cancer a likely diagnosis.
Dhembla urged others to seek medical care if symptoms persist.
“I just wish I had seen a doctor when I was constantly sick every day,” she said. “Just listen to your body. If you’re having symptoms, if you’re sensing something unusual, just please go to a doctor.”
Researchers continue studying immunotherapy’s long-term effectiveness, but oncologists say cases like Dhembla’s demonstrate how personalized treatments are reshaping cancer care.
